Insilico inks another deal with Sino Biopharma unit; Ramaswamy's Datavant to invest in the "patient journey"
→ Insilico — the well-connected AI drug discovery shop that has raised funds at the behest of Shanghai high-flyer WuXi AppTec, Singapore’s Temasek, Peter Diamandis, and Juvenescence — has signed its second deal with a Sino Biopharmaceutical subsidiary. The agreement is with Beijing Tide Pharmaceutical and will focus on cancer drug discovery.
The size of the deal is considerable and is comparable to our previous deal with CTFH, co-founder Alex Zhavoronkov told Endpoints News. The two-program AI drug discovery collaboration inked in 2019 with CTFH made Insilico eligible to receive up to $200 million in milestone payments and royalties.
→ Vivek Ramaswamy‘s Datavant has teamed up to work with Symphony Health, a unit of PRA, to come up with better data analytics covering the “patient journey” in the healthcare system. “Useful data lives in many places, and this partnership will help our customers bring together an even greater amount of data sets for the benefit of their business and the patients whom they serve,” said Doug Fulling, President, Symphony Health. “We are committed to creating a comprehensive view of the patient journey using the largest amount of available de-identified data — all to improve the development and delivery of life-changing therapies.”
→ Fresh off the high of its maiden approval — for an acute CGRP therapy for migraine — Biohaven has secured fast track status from the FDA for its experimental multiple system atrophy drug, verdiperstat, on Friday. The drug is currently being evaluated in a late-stage study involving patients with the rare, progressive and fatal neurodegenerative disease.